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Background Oxidative stress is thought to be involved in the pathogenesis of
asthma. Glutathione-S-transferase (GST) enzymes, which play an
important role in antioxidant defences, may therefore influence
asthma risk. Two common deletion polymorphisms of GSTM1 and
GSTT1 genes and the GSTP1 Ile105Val polymorphism have been
associated with asthma in children and adults, but results are
inconsistent across studies.
Methods Systematic review and meta-analysis of the effects of GST
genes on asthma, wheezing and bronchial hyper-responsiveness
(BHR), with inclusion of unpublished data from three studies,
including the large Avon Longitudinal Study of Parents and
Children (ALSPAC). Random effect or fixed effect models were
used as appropriate, and sensitivity analyses were performed
to assess the impact of study characteristics and quality on
pooled results.
Results The meta-analyses of GSTM1 (n¼22 studies) and GSTT1 (n¼19)
showed increased asthma risk associated with the null genotype,
but there was extreme between-study heterogeneity and publication
bias and the association disappeared when meta-analysis was
restricted to the largest studies. Meta-analysis of GSTP1 Ile105Val
(n¼17) and asthma suggested a possible protective effect of the Val
allele, but heterogeneity was extreme. Few studies evaluated
wheezing and BHR and most reported no associations, although
weak evidence was found for positive associations of GSTM1 null
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539and GSTP1 Val allele with wheezing and a negative association of
GSTP1 Val allele with BHR.
Conclusions Our findings do not support a substantial role of GST genes alone
in the development of asthma. Future studies of large size should
focus on interactions of GST genes with environmental oxidative
exposures and with other genes involved in antioxidant pathways.
Quality of study conduct and reporting needs to be improved to
increase credibility of the evidence accumulating over time.
Keywords Meta-analysis, systematic review, glutathione-S-transferase genes,
GSTM1 gene, GSTT1 gene, GSTP1 gene, asthma, wheezing, bronchial
responsiveness, The Avon Longitudinal Study of Parents and
Children (ALSPAC)
Introduction
Asthma is characterized by chronic airway inflamma-
tion and oxidative stress in the lungs has been impli-
cated in its pathogenesis.
1 Sources of oxidant injury
are reactive oxygen and nitrogen species generated by
activated inflammatory cells and bronchial epithelial
cells and inhalation of atmospheric pollutants, nota-
bly tobacco smoke and oxidant gases, including
ozone, sulphur dioxide and nitrogen oxides.
2 These
are countered by enzymatic and non-enzymatic
antioxidants, including dietary antioxidants, such as
vitamins C and E, and glutathione, a major protective
antioxidant in the lungs that also has a role in
regulation of inflammatory responses.
3 A family of
enzymes, the glutathione-S-transferases (GSTs), has
the general function of conjugating glutathione with
electrophilic substances that are capable of generating
free radicals, thus leading to detoxification of their
effects. Genetic polymorphisms associated with
reduced activity of GSTs are therefore of interest in
the study of disease susceptibility. Two common
deletion polymorphisms of GSTM1 and GSTT1 genes
have been associated with asthma in children and
adults.
4–7 The Val allele of the GSTP1 Ile105Val poly-
morphism, although associated with reduced glu-
tathione activity,
8 has surprisingly been reported to
be highly protective for asthma and airway respon-
siveness in adults.
5,9,10 However, the Val105 allele
has also been reported to increase the risk of
asthma
11 and to increase susceptibility to the effects
of ozone on breathing difficulties in children with
asthma.
12 Others have reported no associations
between this GSTP1 polymorphism and asthma in
children and adults.
4,8,13 Many of the studies were
relatively small or confined to selected populations.
A systematic review of the literature can help under-
stand the reasons for the heterogeneity in study
results, and the pooling of results across similar stud-
ies in a meta-analysis can overcome the problem of
limited statistical power. With this aim, we have con-
ducted a systematic review and meta-analysis on the
associations between GSTM1, GSTT1 and GSTP1 poly-
morphisms and asthma phenotypes in children and
adults, with inclusion of unpublished data from a
large UK cohort study in children, a UK family-
based study in children and young adults and a
Spanish cohort study in children.
Methods
Primary studies
Methods of the three primary studies included in the
meta-analyses are briefly summarized below. Further
details are reported in the Supplementary Appendix 1
available as supplementary data at IJE online.
ALSPAC
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a longitudinal, population-based birth
cohort study that recruited 14541 pregnant women
in 1991–92, with 14062 liveborn children.
14,15
Ethical approval for the study was obtained from
the ALSPAC Law and Ethics Committee and the
Local Research Ethics Committees.
The study collected data on asthma and wheezing in
children at age 7.5 years, based on a questionnaire
sent to mothers. Children from multiple births were
excluded from the analyses. Asthma was defined as a
report of doctor diagnosis of asthma ever together
with reported asthma, wheeze or asthma treatment
in the previous 12 months. Wheezing was defined
as a positive response to the question ‘Has your
child had any wheezing with whistling on his/her
chest when he/she breathed in the past 12
months?’. Spirometry was performed at 8.5 years,
and bronchial hyper-responsiveness (BHR) to metha-
choline was defined as a 20% reduction from baseline
(post-saline) Forced Expired Volume in 1s (FEV1)a t
a cumulative dose of methacholine 41.2mg. In the
mothers’ population, asthma was defined as a positive
response to the question ‘Have you ever had asthma?’,
540 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYfrom a self-completion questionnaire administered
during pregnancy.
The majority of the children’s DNA samples were
extracted from cord blood or venous blood collected
at age 7 years with a small number extracted from
venous blood collected at 43–61 months. The majority
of maternal DNA samples were extracted from blood
taken during pregnancy and a small number were
buccal DNA extracted from mouthwash samples.
16
GSTP1 polymorphism Ile105Val was determined
using competitive allele specific polymerase chain
reaction (PCR) system (KASPar). Copy number vari-
ation (CNV) of GSTT1 and GSTM1 deletion polymorph-
isms was analysed using a real-time PCR method.
17
Genotyping was performed blind to the outcome
status of individuals.
The genetic effects of the three genes were evaluated
using between-genotype comparisons (variant homo-
zygotes vs wild homozygotes and heterozygotes vs
wild homozygotes). Since the samples of mothers and
children were not independent, the odds ratios (ORs)
used in the meta-analysis for the two groups were esti-
mated by analysing them within the same logistic
regression model, and calculating confidence intervals
(CIs) using Huber variances clustered by pregnancy.
AMICS-INMA study
The Menorca Asthma Multicentre Infant Cohort
Study (AMICS) is a population-based birth cohort
included in the Spanish environment and childhood
research network (INMA study). In 1997–98, the
study recruited 482 children at birth from 492 preg-
nant women resident in the island of Menorca, Spain.
The study has been described previously.
18,19 Ethical
approval was obtained from the Balearic Islands
Research Ethics Committee.
Information on asthma and wheezing in children
was collected through telephone questionnaires
administered yearly to mothers, for children up to
the age of 6 years. Presented here are data based on
the questionnaire at age 6 years. Asthma was defined
as doctor-diagnosis of asthma in the previous 12
months, and wheezing as a positive response to the
question ‘Has your child had any wheezing with
whistling on his/her chest when he/she breathed in
the past 12 months?’.
Most of the DNA samples (87%) were extracted
from blood obtained at age 4 years, and the rest
from saliva collected at age 6 years. GSTM1 and
GSTT1 gene deletions were detected by multiplex
PCR, with a method modified from Arand and coll
20
(Supplementary Appendix 1 available as supplemen-
tary data at IJE online). GSTP1 polymorphism
Ile105Val was determined using pyrosequencing
(Biotage, Uppsala, Sweden). All assays were per-
formed blind to the outcome status of the children.
GSTM1 and GSTT1 genetic effects were evaluated
assuming a recessive model (OR for the null
genotype), whereas the genetic effect of GSTP1 was
assessed using between-genotype comparisons.
Southampton study
The Southampton Asthma Cohort is a family study
that started in 1997 and recruited 341 families
(1508 individuals) from Southampton, Portsmouth,
Bournemouth and the Isle of Wight, UK.
21 Inclusion
criteria required two siblings (5–21 years) diagnosed
with asthma and currently using asthma medication.
Reported here are the associations of GSTM1 and
GSTT1 deletion polymorphisms with asthma, defined
as physician’s diagnosis and current use of medica-
tion, and bronchial responsiveness to methacholine,
only measured in participants with a baseline FEV1
570% predicted.
DNA from blood samples was analysed for CNV of
GSTM1 and GSTT1 genes, using quantitative real-time
PCR (Supplementary Appendix 1 available as supple-
mentary data at IJE online). Genotyping was per-
formed blind to the outcome status.
Data were analysed using Family Based Association
Tests (FBAT version 1.4 software; http://www.biostat
.harvard.edu/_fbat.htm), assuming an additive genetic
model with a null hypothesis of ‘no association and
no linkage’ between presence/absence of the gene and
asthma phenotypes.
22
Systematic review
This systematic review was conducted following a
protocol in accordance with the Human Genome
Epidemiology Network (HuGENet) guidelines.
23
Studies were identified through electronic search of
MEDLINE, EMBASE, ISI Web of Science and
HuGENet up to February 2008, using a comprehensive
search strategy (Supplementary Figure S1 available as
supplementary data at IJE online). Included were
population-based and family-based studies examining
the effect of GST polymorphisms on asthma pheno-
types. Although the original search strategy included
atopy, this article focuses on the association of GST
genes with asthma, wheezing and BHR. No restric-
tions were placed on language and type of report,
with inclusion of conference abstracts. When multiple
reports were available for a single study, only the
most recent article or that with the largest sample
size was included. Additional studies were identified
through cross-checking of reference lists of all rele-
vant studies, including previous reviews and editor-
ials. Two reviewers (C.M. and R.G.) independently
extracted data using a pre-piloted form, with a third
reviewer available for arbitration (J.W.H.). Authors of
eligible primary studies were contacted for further
information whenever the data required by the
meta-analysis were not fully reported in the article.
Study quality of primary studies was evaluated
based on the HuGENet guidelines
23 and
STrengthening the REporting of Genetic Association
studies (STREGA) recommendations for the reporting
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24 We also assessed the
epidemiological credibility of the results of our meta-
analyses by use of an index recently proposed for
assessing cumulative evidence in genetic associations
(Venice criteria), which classifies epidemiological
credibility of the results of a meta-analysis as
‘strong’, ‘moderate’ or ‘weak’, based on three ele-
ments: (i) amount of evidence, (ii) extent of replica-
tion and (iii) protection from bias.
25
Meta-analysis
The meta-analyses were performed on the population-
based studies, and included unpublished results from
the ALSPAC and AMICS-INMA studies, together with
those of studies identified through the systematic
review.
Most studies evaluated GSTM1 and GSTT1 as pres-
ence/absence of gene deletion, so that meta-analyses
of these polymorphisms were performed using a
single OR (null vs present). Results for GSTP1
Ile105Val are reported as two ORs, Ile/Val vs Ile/Ile
and Val/Val vs Ile/Ile. Given the absence of a priori
evidence on the genetic model for this polymorphism,
a ‘genetic model-free’ approach was also used to pool
results across genotype groups.
26 This approach does
not assume a specific genetic model but estimates it
from the data, with the only assumption that the
unknown genetic model is constant across studies.
The genetic model-free approach was implemented
within a Bayesian framework and assuming non-
informative prior distributions for all parameters.
27
Details of the model are reported in the Appendix 1.
In the presence of at least five studies, meta-
analyses were performed using random effects
models, which account for between-study heterogene-
ity. If less than five studies were included, meta-
analysis was performed only in the presence of
small between-study heterogeneity (I
2<25%), using
fixed-effect models. The presence of between-study
heterogeneity was investigated using the Q test and
its magnitude estimated using the I
2 statistic, which
measures the proportion of variation across studies
due to genuine differences rather than random
error.
28 Possible causes of heterogeneity were investi-
gated by subgroup analyses based on geographic loca-
tion, population age (adults vs children), size of the
study and definition of asthma. Additional sensitivity
analyses were performed by excluding studies with
poor methodological quality. Studies were considered
of poor quality if no definition of the disease out-
comes was provided and either the description of
the study sample (e.g. selection of cases/controls for
case–control studies) was incomplete or there was no
mention of Hardy–Weinberg equilibrium (HWE).
Although many more items were considered in the
quality assessment, we chose to limit exclusion to
those studies where poor quality seemed beyond any
reasonable doubt.
For each study, deviation from HWE was tested
using the exact test, and the magnitude of the depar-
ture measured using the disequilibrium coefficient.
Studies with large deviations from HWE were further
investigated for possible methodological problems,
including population stratification and genotyping
errors.
29 The presence of small-study bias, which is
a proxy for publication bias, was investigated both
graphically using funnel plots and formally using
Begg’s and Egger’s tests.
All analyses were performed using Stata for Windows
v10 (Stata Corp, College Station, TX, USA), with the
exception of the model-free approach, which was
implemented in WinBUGS 1.4.
30 For the Bayesian anal-
yses, 95% credible intervals (i.e. range in which the
probability that the parameter lies within this interval
is 95%) were calculated in place of 95% CIs.
Results
Primary studies
ALSPAC
For analyses on asthma in children, data were avail-
able from 5327, 5300 and 5330 children for GSTM1,
GSTT1 and GSTP1, respectively; corresponding figures
for wheezing were 5991, 5957 and 5992, and for bron-
chial responsiveness were 3430, 3402 and 3417. For
analyses on asthma in mothers, data were available
from 7049, 7017 and 7262, respectively. The allele
frequencies of GSTM1, GSTT1 and GSTP1 were similar
to those reported in other UK populations
31,32 and in
a White, non-Hispanic US population.
33 All gene poly-
morphisms were in HWE. Overall, there was no evi-
dence of substantial association of the three genes
with asthma phenotypes. The results for GSTM1 and
GSTT1, analysed as CNV with three-level genotype
data, showed no association for GSTM1, whereas a
possible small protective effect on asthma of the
GSTT1 null allele could not be excluded in mothers
(OR: 0.71; 95% CI: 0.57–0.90 and 0.84; 0.63–1.12,
for heterozygotes and null homozygotes, respectively,
compared with wild-type homozygotes). However,
evidence of a possible protective effect was weak in
children (0.91; 0.76–1.11 and 0.89; 0.70–1.13). In chil-
dren, the OR of GSTP1 Ile/Val vs Ile/Ile for asthma was
1.16 (95% CI 0.98–1.37) and for wheezing 1.25 (1.05–
1.49), but such association was not shown for GSTP1
Val/Val vs Ile/Ile, and the finding was not replicated
in mothers. Most subjects in both children’s and
mothers’ groups were White (96 and 98%, respec-
tively), and results did not change when excluding
non-White subjects from the analyses.
AMICS-INMA study
Data were available from 411 and 404 children for
analyses on asthma and wheezing, respectively.
GSTP1 genotype was in HWE. No association was
found between GSTM1 or GSTT1 and asthma or
542 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYwheezing (Figures 2, 3 and 5). GSTP1 showed no
association with asthma, but was associated with
wheezing (Figures 4 and 5). The ORs for GSTP1 and
wheezing were 2.32 (1.03–5.23) and 5.01 (1.72–14.58)
for Ile/Val and Val/Val vs Ile/Ile, respectively, which
suggests that the increased risk of wheezing asso-
ciated with the Val allele might follow an additive
genetic model.
Southampton study
Among the 341 families, the analyses on asthma
included 199 and 224 informative families for
GSTM1 and GSTT1, respectively; these figures were
206 and 227 for bronchial responsiveness. No associ-
ation was found for asthma or bronchial responsive-
ness with either GSTM1 or GSTT1, although the
presence of GSTT1 null allele was associated with an
increased severity score in patients with asthma
(P¼0.015).
Systematic review and meta-analysis
The process of inclusion and exclusion of studies is
presented in Figure 1. Our initial search strategy
identified 804 articles, among which the full text of
87 articles was retrieved for more detailed evaluation.
Of the 30 eligible articles, 2 reported on family-based
studies and 28 articles reported on 26 population-
based studies. We contacted authors of 12 articles
for further information on genotype counts and out-
come definition, and received replies from 5.
Of the 26 eligible population-based studies, we could
include in the meta-analyses data from 25 studies
SEARCH up to Feb. 2008: 804 
AFTER SCREENING OF 
TITLES/ABSTRACTS: 83 
ADDITIONAL PAPERS IDENTIFIED: 4 
￿ Cross-checking  of  references:  3 
￿  Contact with authors: 1 
PAPERS RETRIEVED FOR DETAILED 
EVALUATION: 87  PAPERS EXCLUDED: 57 
￿  Other outcomes (e.g. COPD): 16 
￿  Multiple reports of the same study: 15 
￿ Asthma  severity:  10 
￿ Editorials/reviews:  7 
￿ Occupational  asthma:  6 
￿ Preliminary  results  not  on  GST genes: 2 
￿ Methodological  paper:  1   
PAPERS REVIEWED: 30 
￿ Population  based:  28  (26  studies) 
￿ Family  based:  2   
INCLUDED in GSTM1
meta-analyses: 20 
(19 studies) 
￿ Asthma: 18 (19 studies) 
￿ Wheezing: 2 
￿ BHR: 2 
INCLUDED in GSTT1
meta-analyses: 16 
￿ Asthma: 16 
￿ Wheezing: 0 
￿ BHR: 2 
INCLUDED in GSTP1
meta-analyses: 16 
￿ Asthma: 14 
￿ Wheezing: 1 
￿ BHR: 2 
Figure 1 Flow chart of the inclusion and exclusion of published articles in the review
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2 cross-sectional and 21 case–control studies. After
inclusion of the three primary studies (ALSPAC
mothers, ALSPAC children, AMICS-INMA) associa-
tion with asthma was evaluated in 22 studies on
GSTM1,1 9o nGSTT1 and 17 on GSTP1. Asthma was
defined as doctor-diagnosed asthma in 19, 16 and 12
studies on GSTM1, GSTT1 and GSTP1, respectively.
Wheezing was evaluated in four studies on GSTM1,
two on GSTT1 and three on GSTP1. BHR, defined in
all studies as a FEV1 reduction of 520% after metha-
choline challenge, was considered in three studies on
GSTM1, three on GSTT1 and three on GSTP1. Overall,
10 studies were performed in children, 7 in adults,
6 in both, whereas for 2 studies the information
was not available. In terms of geographical location,
13 studies were performed in Asia, 8 in Europe, 2 in
North Africa and 2 in North America. Case–control
studies varied in sample size, from less than 100 to
approximately 1000. On the other hand, both cross-
sectional studies had around 3000 subjects and three
out of five cohort studies had large sample size of
4400–7200. Other characteristics of the population-
based studies included in the meta-analyses are sum-
marized in Table 1, and genotype counts by disease
outcome are reported in Table 2.
Two family studies were included in the systematic
review (Table 1), but only one provided complete
Table 1 Characteristics of the studies evaluating the effects of GST genes on asthma risk, wheezing and BHR
Study, year Study population
Location,
ethnicity
Adults/
children
Sample
size
a Definition of disease outcome
Case–control studies (n¼21)
Fryer,
2000
9
Cases: from patient database
Controls: healthy volunteers
UK,
European
Adults 171 Atopic asthma diagnosed by a
physician [Criteria: a history of
wheezing, cough, dyspnoea and/or
chest tightness; spirometric demon-
stration of airflow obstruction
reversible with ab-agonist broncho-
dilator (415% change in FEV1); and
positive atopic status) BHR FEV1
reduction420% after methacholine]
Chung,
2002
59
Cases and controls: from
cohort of civil servants
and their families
Korea, Asian N/A 99 Asthma diagnosed by a physician
(Criteria: symptoms of wheezing/
chest tightness and FEV1 reduction
420% after methacholine challenge)
Freidin,
2002
60
Cases: hospitalized patients
Controls: healthy volunteers
Russia, Asian N/A 126 Atopic asthma diagnosed by a
physician (Criteria: N/A)
Sideleva,
2002
61
Cases: hospitalized patients
Controls: healthy volunteers
Russia,
European
Both 199 Atopic asthma diagnosed by a
physician (Criteria: the commonly
accepted clinical laboratory exami-
nation and analysis of the external
respiration function
62)
Vavilin,
2002;
39
Safronova,
2003
38
Cases: hospitalized patients
Controls: healthy volunteers
Russia,
European
Children 237 Asthma diagnosed by a physician
(Criteria: N/A)
Aynacioglu,
2004
41
Cases: consecutive asthma
outpatients
Controls: healthy volunteers
Turkey,
Asian
Adults 475 Asthma diagnosed by a physician
(Criteria: ECRHS protocol; medical
history, physical examination, lung
function tests, chest X-rays, SPT,
TOT IgE)
Saadat,
2004
6
Cases: N/A
Controls: healthy volunteers
Iran, Asian Both 170 Asthma diagnosed by a physician
[Yes to two or more criteria: (i)
history of wheezing/breathlessness;
(ii) airflow obstruction of 415%
FEV1; and (iii) PEF 420%]
Tamer,
2004
11
Cases: hospitalized patients
Controls: healthy volunteers
Turkey,
Asian
Adults 204 Asthma diagnosed by a physician
(Criteria: American Thoracic Society
statement
63)
Zhang,
2004
36
Cases: hospitalized patients
Controls: N/A
China, Asian Adults 120 Asthma diagnosed by a physician
(Criteria: N/A)
(Continued)
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Study, year Study population
Location,
ethnicity
Adults/
children
Sample
size
a Definition of disease outcome
Lee, 2005,
2008
10,64
Cases: school children
from three communities
Controls: healthy random
sample from same three
communities
Taiwan,
Asian
Children 397 Asthma parent-reported (positive
response to the question, ‘Has a
physician ever diagnosed your child
as having asthma?’) Wheezing
parent-reported (lifetime history)
Nickel,
2005
13
Cases: from Multicenter
Allergy Study
Controls: healthy volunteers
Germany,
European
Children 205 Asthma diagnosed by a physician
(Criteria: one or more episodes of
wheezingduringprevious12months)
Oh,
2005
37
Cases: recruited at an
allergy clinic
Controls: healthy subjects
Korea, Asian Both 273 Asthma diagnosed by a physician
(Criteria: N/A)
Arbag,
2006
65
Cases: cases of nasal polyposis
Controls: healthy individuals
from same geographic location
and same ethnicity as cases
Turkey,
Asian
Both 133 Asthma diagnosed by a physician
(Criteria: N/A; cases were receiving
regular inhaled corticosteroids and
beta2-adrenoreceptor stimulants for
use as required)
Ercan,
2006
1
Cases: random sample from
cohort of asthmatic children
Controls: healthy school
children
Turkey,
Asian
Children 563 Asthma diagnosed by a physician
[Criteria: history of intermittent
wheezing and the presence of
reversible airway obstruction as
defined by at least a 12% improve-
ment in FEV1 following bronchodi-
lator administration, therapeutic
response to anti-asthma treatment,
or an abnormal result in metha-
choline bronchoprovocation test
(PC20<8mg/dl)]
Holla,
2006
66
Cases and controls are unre-
lated subjects selected from
questionnaires
Czech
Republic,
European
Both 637 Asthma diagnosed by a physician
(Criteria: asthma symptoms and use
of antiasthma medication according
to the GINA guidelines
67)
Plutecka,
2006
35
Cases: N/A
Controls: healthy volunteers
Poland,
European
Adults 496 Asthma not defined
Abdel-Alim,
2007
40
Cases: children attending out-
patient clinic of allergy and
immunology
Controls: matched healthy
children enrolled in this work
Egypt, North
African
Children 90 Asthma diagnosed by a physician
(Criteria: GINA guidelines
68)
Hanene,
2007
5
Cases and controls from
a representative region
Tunisia,
North African
Children 347 Asthma not defined
Kamada,
2007a
69
Cases: recruited from a
medical centre
Controls: healthy volunteers
Japan, Asian Both 980 Asthma diagnosed by a physician
(Criteria: American Thoracic
Society
70)
Kamada,
2007b
69
Cases: recruited from a
medical centre
Controls: healthy volunteers
Japan, Asian Children 289 Asthma diagnosed by a physician
(Criteria: American Thoracic
Society
70)
Mak,
2007
8
Cases: recruited from
asthma clinic Controls:
random healthy subjects from
Hong-Kong population
China, Asian Adults 626 Asthma diagnosed by a physician
(Criteria: cough/wheeze/chest tight-
ness and airflow obstruction of
515% FEV1)
Cohort studies (n¼5)
Imboden,
2007
71
SAPALDIA—a prospective
multicentre study on adult
Swiss general population,
investigating environmental
and genetic effects on lung
Switzerland,
European
Adults 4422 Asthma self-reported (positive
response to ‘Have you ever had
asthma?’ and ‘Was this confirmed
by a doctor?’) BHR FEV1 reduction
420% after methacholine
(Continued)
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Study, year Study population
Location,
ethnicity
Adults/
children
Sample
size
a Definition of disease outcome
Schroer
2009
42
CCAAPS study on allergy and
air pollution in infants with
at least one atopic parent
US, mixed
ethnicity
Children 498 Wheezing parent-reported (paren-
tal report of the child wheezing at
least once at 2 years in last 12
months)
ALSPAC
mothers
ALSPAC—a UK population-
based birth cohort, with
pregnant women recruited in
1990
UK,
European
Adults 7262 Asthma self-reported (history of
asthma reported in a questionnaire
administered during pregnancy)
ALSPAC
children
ALSPAC—children recruited
at birth and followed up to
investigate their health,
behaviour and development
UK,
European
Children 5330 Asthma parent-reported (positive
response to ‘Has a doctor ever said
that your child has asthma?’ at
7 years) Wheezing parent-reported
(current history) BHR FEV1 reduc-
tion 420% after methacholine
AMICS-
INMA
AMICS—a population-based
birth cohort included in the
Spanish environment and
childhood research network
(INMA study)
Spain,
European
Children 428 Asthma parent-reported (positive
response to ‘Has your child had any
wheezing with whistling on his/her
chest when he/she breathed in the
past 12 months?’ at age 6 years)
Wheezing parent-reported (current
wheeze at 6 years)
Cross-sectional studies (n¼2)
Salam
2007;
7
Gilliland,
2002
33
Cross-sectional study as part
of the Children Health Study,
a Californian ongoing cohort
study of school children
in 12 communities
US, Mixed
ethnicity
Children 3081 Asthma parent-reported DDA
(Criteria: N/A) Wheezing parent-
reported (lifetime history)
Kabesch
2004
53
Cross-sectional study part of
ISAAC project, assessing
prevalence of asthma and
allergy in school children
Germany,
European
Children 3005 Asthma parent-reported DDA
(Criteria: N/A)
Family studies (n¼3)
David
2003
34
Family study based on
case–parent triad design and
focused on gene–environment
interactions
Mexico,
Latin
American
Children 218
families
Asthma diagnosed by a physician
(Criteria: included skin-prick and
pulmonary function testing)
Brasch-
Andersen
2004
4
Family study that recruited
atopic families with asthmatic
children in two separate
samples. Sample A: asthma;
Sample B: atopic asthma
Denmark,
European
Children 246
families
(Sample A) Asthma diagnosed by
a physician (Criteria: clinical symp-
toms plus positive methacholine
challenge)
(Sample B) Atopic asthma diag-
nosed by a physician (Criteria:
clinical symptoms plus positive
specific IgE measurement)
Southa-
mpton
UK multicentre family
study that recruited families
with two siblings diagnosed
with asthma
UK,
European
Children
and young
adults
341
families
Asthma self and parent reported
(Criteria: three positive responses
to: ‘Have you ever had asthma?’
and, ‘Was this confirmed by a
doctor?’ and, ‘Have you used any
medicines to treat asthma, or any
breathing problems, at any time in
the last 12 months’) Bronchial
responsiveness methacholine dose
response measure
N/A: not available; DDA: doctor-diagnosed asthma; GINA: global initiative on asthma.
aWhen results are reported for more genotypes or outcomes, the largest sample size is reported.
ECRHS: european community respiratory health survey; SPT: skin prick tests; TOT: total; SAPALDIA: swiss cohort study on air
pollution and lung and heart diseases in adults; CCAAPS: cincinnati childhood allergy and air pollution study; ISAAC: international
study of asthma and allergies in childhood
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4 and no meta-analysis could be performed.
The study by Brasch-Andersen and colleagues,
4 con-
sisting of 246 Danish atopic families (452 asthmatic
children plus their parents) recruited in two separate
samples, evaluated the risk of asthma and atopic
asthma associated with the three genes. GSTM1 and
GSTT1 were analysed as CNV with full gene-dosage
information available. The study found strong evi-
dence of an association of the GSTM1 homozygous
deletion with asthma (P<0.0005), which became
even stronger when limiting the analyses to atopic
asthma (P<0.00005). An association of GSTT1 with
asthma was also found, but under an additive model
(P¼0.019), with similar results obtained for atopic
asthma (P¼0.021), whereas no association was
found with GSTP1. The study by David and collea-
gues,
34 consisting of 218 Mexican case–parent triads,
focused on the interaction between NQO1 (Pro187Ser
polymorphism) and GSTM1 genes in increasing the
risk of asthma in children exposed to high level of
ozone (Mexico City). The study, which evaluated
GSTM1 in terms of null genotype (homozygous dele-
tion), did not assess the effect of GSTM1 alone, but
showed a protective effect of the NQO1 Ser allele in
children with null GSTM1 genotype.
Quality of the studies included
We assessed the quality of the 27 articles, reporting
on the 25 studies included in the meta-analyses, and
the 2 family-based articles. Three articles
6,35,36 did not
describe the study population (selection of cases and/
or controls for case–control studies), and six arti-
cles
5,35–39 did not provide a definition of the outcome
considered (asthma in all cases). HWE was reported
to be assessed in less than half of the articles (46%).
All studies described the genotyping methods used.
Genotyping error was evaluated in a quarter of
them, mainly by repeating the genotyping in 5–15%
of the samples, and no errors were found in most
cases. However, only 14% of the studies reported
blinding of genotyping to the clinical status of the
subjects. Among the population-based studies, 35%
of the articles discussed the issue of population strat-
ification, although only a few discussed the potential
problem in some detail.
Four studies were identified as being of poor quality
(no outcome definition plus incomplete description of
study population/no assessment of HWE). All of them
were case–control studies with total sample size less
than 500, and they were published in Russian,
39
Chinese,
36 Korean
37 and international
35 journals.
Table 2 shows deviation from HWE for GSTP1 gene
in four studies of relatively small size (less than 500),
including three case–control studies of rather poor
quality,
38,40,41 and a cohort study
42. Only two of
them
41,42 performed quality control of genotyping
and found no genotyping error, and none of them
reported blinded genotyping. Only one of them
42
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548 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYmentioned the possibility that population stratifica-
tion might have occurred.
Meta-analyses on GSTM1 deletion polymorphism
A total of 19 published and 3 primary studies evalu-
ated the association of GSTM1 and asthma, including
a total of 4416 affected and 23902 non-affected indi-
viduals. The meta-analysis in Figure 2a shows an
increased risk of asthma associated with the GSTM1
null genotype (pooled OR 1.28; 95% CI 1.09–1.52).
However, large between-study heterogeneity was
observed (I
2¼76%), which could not be explained
by age (adults/children) or ethnicity, as approximated
by study geographical location (continent). These sub-
group analyses, however, showed that most heteroge-
neity was present in studies on adults and in those
performed in Asia (Supplementary Figure S2 available
as supplementary data at IJE online). Similarly, exclu-
sion of two studies with poor quality
36,39 reduced the
pooled OR to 1.19 (1.03–1.38) with little reduction of
the I
2 (69%). The subgroup analysis by asthma defi-
nition (Figure 2b) could not explain heterogeneity
either, although it showed that heterogeneity was
limited to studies where asthma was diagnosed by a
physician and where asthma was not defined in the
article, whereas it was absent among studies with
self-reported asthma. However, studies using self-
reported asthma included those with the largest
sample size, therefore it is difficult to disentangle
the impact of asthma definition from that of study
size on the observed heterogeneity. In fact, the
funnel plot in Figure 2c strongly supports the pres-
ence of small-study bias. When the meta-analysis was
repeated by limiting inclusion to the nine studies at
the top of the funnel, the heterogeneity dropped from
76 to 38% and the OR became very close to 1 (1.02;
0.92–1.13).
As for the association of GSTM1 null genotype with
wheezing and BHR, only four and three studies were
available, respectively. As shown in Figure 5a, for
both outcomes results were very homogeneous
across studies. The meta-analysis showed no effect
on BHR (1.01; 0.90–1.15), and only a possible small
effect on wheezing (1.08; 0.99–1.19).
Meta-analyses on GSTT1 deletion polymorphism
A total of 16 published and 3 primary studies evalu-
ated the association of GSTT1 and asthma, including
3852 affected and 22880 non-affected individuals.
Similarly to GSTM1, the meta-analysis in Figure 3a
shows an OR of 1.39 (1.09–1.77), but with extreme
between-study heterogeneity (I
2¼81%). As for
GSTM1, heterogeneity was absent within the subgroup
of studies with self-reported asthma (Figure 3b), and
small-study bias was the only factor substantially
explaining heterogeneity. When restricting the meta-
analysis to the nine largest studies at the top of the
funnel plot in Figure 3c, the OR became 0.93 (0.84–
1.03) and the heterogeneity disappeared (I
2¼0%).
On the contrary, exclusion of the two studies with
poor quality
36,39 reduced the pooled OR to 1.19
(0.97–1.44), but did not reduce substantially the
degree of heterogeneity (I
2¼70%). Subgroup
analyses by age and ethnicity did not provide addi-
tional insight on the causes of heterogeneity
(Supplementary Figure S3 available as supplementary
data at IJE online).
Similarly to GSTM1, the association of GSTT1 with
wheezing and BHR (Figure 5b) showed homogeneous
results across studies (two and three studies included,
respectively). The meta-analyses showed no genetic
effect for either outcome (wheezing 1.05; 0.86–1.30;
BHR 0.96; 0.81–1.13).
Meta-analyses on GSTP1 Ile105Val polymorphism
A total of 14 published and 3 primary studies with
3363 affected and 14442 non-affected individuals
were available for the meta-analysis of GSTP1 Ile/Val
vs Ile/Ile and asthma, whereas 13 published and 3
primary studies with 2160 affected and 9034 non-
affected individuals were available for the contrast
Val/Val vs Ile/Ile (Figure 4; Supplementary Figure S4
and S5 available as supplementary data at IJE online).
The meta-analyses in Figure 4 show no clear associa-
tion of GSTP1 with asthma, although the two pooled
estimates point to a possible protective effect of the
Val allele, with an OR of 0.93 (0.82–1.06) for Ile/Val
vs Ile/Ile and 0.79 (0.57–1.08) for Val/Val vs Ile/Ile.
Although between-study heterogeneity was moderate
for Ile/Val vs Ile/Ile (I
2¼39%), it was large for Val/Val
vs Ile/Ile (72%), so that the result for the latter is
difficult to interpret. Heterogeneity could not be
explained by small-study bias (Supplementary
Figure S5c available as supplementary data at IJE
online), and was not reduced by removing the two
studies with poor quality
35,37 either. Ethnicity did
explain some heterogeneity (Supplementary Figure
S5b available as supplementary data at IJE online),
and exclusion of the two North African studies
(Egypt and Tunisia) brought the ORs close to
1 (Ile/Val vs Ile/Ile 0.98; 0.87–1.10, and Val/Val vs
Ile/Ile 0.94; 0.71–1.24) and reduced I
2 to 59%.
Pooling of the two African studies showed a marked
protective effect (Ile/Val vs Ile/Ile 0.52; 0.33–0.83, and
Val/Val vs Ile/Ile 0.24; 0.09–0.69). The subgroup
analysis by asthma definition showed similar results
as for GSTM1 and GSTT1, with no heterogeneity within
studies with self-reported asthma (Figure 4c and d).
Only three studies were available for the association
of GSTP1 with wheezing and BHR, and meta-analysis
could only be performed for the comparison of
Ile/Val vs Ile/Ile where the heterogeneity was small
(Figure 5c and d). For the Ile/Val vs Ile/Ile comparison
there is a suggestion of an increased risk associated
with the Val allele for both outcomes. Effects in oppo-
site directions are shown for the Val/Val vs Ile/Ile
comparison, with the Val allele having a protective
effect on BHR as with asthma, but being associated
GLUTATHIONE-S-TRANSFERASE GENES AND ASTHMA PHENOTYPES 549with increased risk of wheezing. These findings need
to be interpreted with caution since they are driven
by two relatively small studies, the study by Fryer
9
and the AMICS-INMA study, respectively.
The results of the analyses based on the model-free
approach were similar to those based on between-
genotype comparisons, giving an OR of 0.93 (0.77–
1.03) for Ile/Val vs Ile/Ile and 0.77 (0.49–1.14) for Val/
Val vs Ile/Ile. The model-free approach provided an
estimate of , the parameter indicating the underlying
genetic model, of 0.27 (0.01–0.61), where 0 corre-
sponds to the recessive, 0.5 to the co-dominant and 1
to the dominant model.
26 Despite the wide CI, the esti-
mate of  seems to exclude a dominant genetic model
and suggests either a co-dominant or a recessive model.
Strength of the evidence from the meta-analyses
When applying the Venice criteria to assess credibil-
ity,
25 the cumulative evidence reviewed does not
clearly support a genetic effect for any of the three
GST genes on asthma. In fact, although the amount of
evidence is good for all three meta-analyses,
particularly those on GSTM1 and GSTT1, the degree
of heterogeneity across studies and the likely presence
of publication bias make the credibility of the evi-
dence weak. Moreover, when limiting the meta-
analyses to the largest studies, positive findings
shown by other studies could not be replicated, sug-
gesting that a genetic effect is likely to be either
absent or very small.
Discussion
Overall, the evidence synthesized in this review does
not support a substantial role of GST genes on asthma
phenotypes in either children or adults, although
small effects cannot be excluded and it is possible
that these genes act on airway disease through inter-
action with environmental exposures or other genes.
The weakness of the available evidence in supporting
an effect of GST genes on asthma is mainly due to
publication bias and large heterogeneity of study
results. Interestingly, the results from the three
(a)
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Figure 2 Random effects meta-analysis of GSTM1 (null vs present) effect on asthma: (a) forest plot for the main analysis;
(b) forest plot for the subgroup analysis by asthma diagnosis; (c) funnel plot, where studies classified as ‘small’ or ‘large’ in
the sensitivity analyses are represented by dots and triangles, respectively (Egger’s test: P¼0.035; Begg’s test: P¼0.135)
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Figure 2 Continued
GLUTATHIONE-S-TRANSFERASE GENES AND ASTHMA PHENOTYPES 551unpublished studies on GST genes and asthma pheno-
types were negative. The only exception was the asso-
ciation between GSTP1 and wheezing (but not
asthma) in the AMICS-INMA study, which suggested
an increased risk for the Val allele. It is important to
note that the ALSPAC, which provided negative
results consistently for all GST genes and asthma phe-
notypes, was the largest study included in all the
meta-analyses. In fact, the plan for the systematic
review and meta-analysis presented here originated
with the aim of putting the results of the ALSPAC
cohort into context, and understand the reasons for
the apparent disagreement with previous published
studies. The lack of evidence of an important role of
GST genes in the development of asthma, wheezing
and BHR is in agreement with negative findings on
lung function in children for all three GST genes from
the ALSPAC (data not shown), although an association
between GSTM1 and GSTP1 genes and lung function in
childhood has been previously suggested.
43
Although the meta-analyses on GSTM1 and GSTT1
with inclusion of all studies showed an increased
risk of asthma associated with the two null geno-
types, the presence of small-study bias and extreme
heterogeneity in study results make the credibility of
these findings very low. Despite our efforts to be as
inclusive as possible (comprehensive search strategy,
avoidance of language restrictions, inclusion of con-
ference abstracts), the meta-analyses showed clear
absence of small studies with negative results, sug-
gesting the presence of publication bias. This is an
important issue in meta-analysis of genetic associa-
tion studies, which needs to be highlighted and
addressed. We did so by repeating the analyses with
inclusion of only the largest studies, and we found
loss of the observed associations, with ORs very
close to 1. Positive results were not only confined to
small studies, but also to studies with poor quality,
the exclusion of which caused similar loss of the
observed associations. In support of an absence of
an association of GSTM1 and GSTT1 with airway dis-
ease are the negative findings of the meta-analyses on
wheezing and BHR. An exception might be the asso-
ciation between GSTM1 and wheezing, where the
NOTE: Weights are from random effects analysis
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Figure 3 Random effects meta-analysis of GSTT1 (null vs present) effect on asthma: (a) forest plot for the main analysis;
(b) forest plot for the subgroup analysis by asthma diagnosis; (c) funnel plot, where studies classified as ‘small’ or ‘large’ in
the sensitivity analyses are represented by dots and triangles, respectively (Egger’s test: P¼0.003; Begg’s test: P¼0.001)
552 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYmeta-analysis suggests a possible small effect of the
null genotype in increasing the risk of  10%.
Although the studies included in the meta-analyses
on wheezing and BHR were only few and the results
supported only weak evidence of associations, the con-
sistency in results and narrow CIs of the ORs give some
credibility to these findings. An important method-
ological point regarding studies on GSTT1 or GSTM1 is
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Figure 4 Random effects meta-analysis of GSTP1 effect on asthma: (a) Ile/Val vs Ile/Ile; (b) Val/Val vs Ile/Ile; (c) subgroup
analysis by asthma diagnosis for Ile/Val vs Ile/Ile; (d) subgroup analysis by asthma diagnosis for Val/Val vs Ile/Ile
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cannot distinguish between genotypes with one or
two copies of the gene. By classifying the genotype as
‘present’ or ‘null’ they imply a recessive model (one or
two copies vs absence of the risk allele), which may not
reflect the true underlying genetic model and thus may
not provide a valid and accurate estimate of the genetic
risk. GSTT1 or GSTM1 CNVs (also known as ‘gene
dosage’) are correlated with altered enzyme activity,
and analysis in a dose-dependent manner would best
describe any disease outcome association.
44,45 Brasch–
Andersen and colleagues have shown that it is possible
to utilize the increased sensitivity of real-time PCR
assays to provide dosage of GSTT1 and GSTM1.
4 A
similar approach was utilized to obtain gene-dosage
information in the ALSPAC cohort.
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556 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYThe meta-analysis on GSTP1 Ile105Val polymorph-
ism and asthma suggested a possible, weak protective
effect of the Val allele. The Val substitution in the
GSTP1 gene is associated with altered substrate affi-
nities compared with the Ile105 wild-type allele
46 and
heterozygosity has also been associated with reduced
risk of chronic obstructive pulmonary disease.
47
Although in the meta-analysis on GSTP1 and asthma
there was no clear evidence of small-study bias, het-
erogeneity in study results was large and limited the
interpretability of the pooled estimates. Subgroup
analyses showed a potential role of ethnicity in
explaining such heterogeneity, with a protective
effect of the Val allele limited to the two North
African studies, where the association was very
strong. This finding might be explained by the pres-
ence of gene–environment or gene–gene interactions
in these study populations. GST genes effects on
asthma risk may be modified by exposures that pro-
duce lung oxidative injury, such as smoking, air
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speculate that smoking in North African countries is
a major problem, and the common waterpipe smoking
seems to produce even more free radicals than ciga-
rette smoking.
48 The value of such speculations is lim-
ited in the absence of supporting evidence, and bias
associated with selective reporting or poor quality
might be an alternative explanation for the positive
findings of the two North African studies. Future
research in these populations should collect informa-
tion on factors potentially interacting with GST genes
in modifying asthma risk, including oxidative expo-
sures. Only few studies evaluated the effects of GSTP1
on wheezing and BHR, and the findings were in
opposite directions for the two outcomes. The Val
allele was protective for BHR, in agreement with the
results for asthma, but associated with increased risk
of wheezing. These effects were suggested by two rel-
atively small studies, whereas the large ALSPAC
cohort did not provide convincing evidence of any
association with either outcome.
Failure to account for environmental exposures
in our meta-analyses might partly explain not
only the heterogeneity of results across studies,
but also the overall negative findings. Strong environ-
mental effects on asthma phenotypes could mask
modest genetic effects and, more importantly, gene–
environment interactions could make the effects of
GST genes become substantial only in the presence
of oxidative exposures and not detectable at a popu-
lation level.
49 Passive smoking, ambient air pollution
and endotoxin or other pathogen-associated mole-
cules are good candidates for gene–environment inter-
actions in asthma, particularly with genes involved in
antioxidant defence, such as the GST genes.
49–51 In
our review, variation in exposure to these environ-
mental factors across studies is likely to have hap-
pened given the diverse geographical setting of the
studies included, and gene–environment interactions
might partly explain the large heterogeneity observed.
Moreover, there is evidence that antioxidant supple-
mentation can modify these gene–environment inter-
active effects,
52 so that the nutritional status of the
study population could represent an additional source
of heterogeneity. The evaluation of gene–environment
interactions is problematic due to the lack of power of
statistical tests for interactions and the high measure-
ment error present in the assessment of most envi-
ronmental exposures. In fact, despite the strong
biological rationale, results from the literature on
gene–environment interactions in asthma remain
inconclusive.
51 Only a small proportion of the studies
reviewed in this article reported on gene–environment
interactions, including environmental tobacco
smoke (ETS),
33,39,53 in utero ETS
33,53 and air pollu-
tion,
7,54 and the same environmental exposure was
assessed in different ways across studies.
Researchers interested in the effects of GST genes
should be encouraged to collect information on
relevant environmental exposures and carefully
choose the methods to measure them.
Standardization of methods for environmental expo-
sure assessment and full reporting of the interactions
tested will allow the pooling of data across studies
and to reach adequate power to detect interactions.
The study of possible interactions between GST
genes and environmental exposures on asthma is
important not only for our understanding of the etio-
pathogenesis of this complex disease, but also for its
possible implications for public health. Asthma prev-
alence is high and increasing over time worldwide,
and GST genes polymorphisms are frequent in the
population, particularly the GSTM1 null genotype,
with reported frequencies in different ethnic groups
varying from 18 to 66%.
55 The possibility of imple-
menting simple measures such as antioxidant diet
supplementation in subjects at risk makes this topic
worthwhile for further research.
GSTs Mu-1, Theta-1 and Pi-1 have overlapping sub-
strate specificities, so that a deficiency in one isoform
may be compensated by another. A meta-analysis of
14 studies showed that adults with a combined
GSTM1 and GSTT1 null genotype were at a higher
risk of asthma (OR 2.15, 95% CI 1.21–3.71) and sug-
gested that smoking overloads the capacity of either
GSTM1 or GSTT1 detoxification systems.
56 We investi-
gated the effect of the combined null genotype using
published data from 16 studies and unpublished data
from the ALSPAC and AMICS-INMA study (data not
shown). Although we found an association with
increased asthma risk (OR 1.39, 95% CI 1.16–1.67),
the extreme between-study heterogeneity (I
2¼88%)
and presence of publication bias greatly limit the
credibility of these findings. Moreover, the results
from the ALSPAC, which represented the largest
sample in the meta-analysis, were negative. On the
other hand, GST genes could interact with genes
coding for other detoxifying enzymes induced in
response to oxidative stress. Supporting this hypothe-
sis is some evidence of interaction between GSTM1
null genotype and NQO1 Pro187Ser polymorphism
on asthma.
34 Future large studies evaluating GST
genes in addition to other antioxidant genes are
needed to provide evidence on gene–gene interactive
effects on asthma.
This systematic review only focussed on asthma risk,
and did not consider the possible association of GST
genes with asthma severity in patients affected by the
disease. A finding from the Southampton study was
the association of the GSTT1 null allele with an
increased severity score in patients with asthma (data
not shown). There is evidence suggesting that GST
genes, in particular GSTM1 and GSTP1, might also inter-
act with air pollution and tobacco smoke exposures in
exacerbating respiratory symptoms and decreasing
lung function in asthmatic individuals.
12,32,57
Despite our attempt to investigate causes of hetero-
geneity in study results in the meta-analyses
558 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYpresented, we were limited by the availability of rele-
vant information in the published reports. For exam-
ple, although we did not find evidence of effect
modification by ethnicity and age at onset, we
cannot exclude the contribution of these factors to
the observed heterogeneity, given that we used
crude proxies for them (study geographical location
for ethnicity, and age of study population instead of
age at onset for childhood vs adult asthma).
Differences in asthma definition may also have
played a role in generating the observed heterogene-
ity. Asthma diagnosed by a physician, self-reported
doctor-diagnosed asthma and self-reported history of
asthma differ in sensitivity and specificity.
58
Moreover, asthmatic individuals identified through
questionnaire in a population-based study may have
lower severity than patients recruited at a clinic.
Although asthma definition could not explain hetero-
geneity in our meta-analyses, heterogeneity was not
present within the subgroup of studies that used self-
reported asthma, where effects were closer to the null
hypothesis compared with studies that used physi-
cian-diagnosed asthma and those that did not report
how asthma was defined. However, interpretation of
this finding is difficult, since we could not disentangle
the possible effect of asthma definition from that of
study design and study size. Physician-diagnosed
asthma was used by relatively small case–control stu-
dies, whereas self-reported asthma was used by large
cohort and cross-sectional studies. The presence of
publication bias, for example, could in theory explain
the fact that heterogeneity was limited to the smallest
studies, which happened to be case–control studies
with physician-diagnosed asthma.
In conclusion, the evidence reviewed in this article
does not support a substantial role of GST genes alone
in the development of asthma. However, given the
potential for interactions between GST genes and
environmental toxins known to cause oxidative
damage to the lungs, future research should be
planned to explore gene–environment interactions.
Large studies with accurate measurement of the envi-
ronmental exposure are needed in order to reach ade-
quate power to detect such interactions. Similarly,
further research should evaluate possible interactions
between GST genes and other genes involved in the
antioxidant pathway. Future studies will also need to
improve their methodological quality and the report-
ing of their findings, in order to increase the credibil-
ity of the evidence accumulating over time.
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KEY MESSAGES
  Oxidative stress is involved in the pathogenesis of asthma, and glutathione-S-transferase (GST)
enzymes may therefore influence asthma risk.
  Common polymorphisms of the GSTM1, GSTT1 and GSTP1 genes have been associated with asthma in
children and adults, but published results are inconsistent across studies.
  Our meta-analyses do not support a substantial role of the GST genes alone in the development of
asthma, and they suggest presence of publication bias.
  Future studies should focus on possible interactions of the GST genes with environmental oxidative
exposures and with other genes involved in the antioxidant pathway.
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Appendix 1
WinBUGS code for the genetic model-free approach
Model
{
for(i in 1:17) {
case[i,1:3]   dmulti(p.case[i,], N.case[i])
control[i,1:3]   dmulti(p.ctrl[i,], N.ctrl[i])
p.ctrl[i,1] <- 1/(1þbeta[i,1]þbeta[i,2])
p.ctrl[i,2] <- beta[i,1]/(1þbeta[i,1]þbeta[i,2])
p.ctrl[i,3] <- beta[i,2]/(1þbeta[i,1]þbeta[i,2])
beta[i,1]   dgamma(0.001,0.001)
beta[i,2]   dgamma(0.001,0.001)
p.case[i,1] <- 1/(1þtheta[i,1]þ theta [i,2])
p.case[i,2] <- theta [i,1]/(1þ theta[i,1]þ theta [i,2])
p.case[i,3] <- theta [i,2]/(1þ theta[i,1]þ theta [i,2])
theta[i,1] <- beta[i,1]
 exp(lambda
 delta[i])
theta[i,2] <- beta[i,2]
 exp(delta[i])
delta[i]   dnorm(d, prec)
}
d   dnorm(0.0,1.0E-6)
lambda   dbeta(0.5,0.5)
prec <- 1/var
var <- pow(sd,2)
sd   dnorm(0,1)I(0,)
OR_Gg <- exp(lambda
 d)
OR_GG <- exp(d)
}
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